Rociletinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor widely used for non-small cell lung cancer patients, was highly abundant in 7 cancers especially in LIHC49. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.